GSK plc
Ticker(s):
GSK and GLAXF
Country:
Sector & Industry:
Business Overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson’s disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.
Contact & Other Information
Number of Employees:
68,629
Website:
,
,
GSK plc reports the acquisition of ordinary shares under the Company’s Share Reward Plan by multiple directors and key personnel on March 11, 2025.
03/14/2025 | 6-K | 0001654954-25-002757 |GSK plc announces the purchase of 755,000 ordinary shares as part of its existing buyback program.
02/21/2025 | 6-K | 0001654954-25-001750 |GSK plc announced that Dr. Gavin Screaton will join the Board as a Non-Executive Director, replacing Dr. Jesse Goodman who is retiring.
02/21/2025 | 6-K | 0001654954-25-001748 |GSK plc granted conditional share awards to its Persons Discharging Managerial Responsibilities under the GlaxoSmithKline 2017 Performance Share Plan.
02/21/2025 | 6-K | 0001654954-25-001746 |GSK plc granted deferred annual bonus plan awards to its Persons Discharging Managerial Responsibilities (PDMRs) on February 17, 2025.
02/21/2025 | 6-K | 0001654954-25-001744 |Tony Wood, Chief Scientific Officer of GSK plc, received a cash payment related to vested shares under the GlaxoSmithKline Deferred Investment Award Programme.
02/21/2025 | 6-K | 0001654954-25-001742 |GSK plc reports the vesting of performance share plan awards to PDMRs and their PCAs, along with subsequent sales to cover tax liabilities.
02/21/2025 | 6-K | 0001654954-25-001726 |GSK plc reports the vesting of conditional share awards under the Share Value Plan for PDMRs and the subsequent sale of ordinary shares to cover tax liabilities.
02/21/2025 | 6-K | 0001654954-25-001724 |GSK plc reports the vesting of deferred bonus awards and subsequent sale of ordinary shares and American Depositary Shares by Persons Discharging Managerial Responsibilities to meet tax liabilities.